CLDF Title
Home | Contact Us | Bookmark
Embassy of Education
Live Events Slide Library Webcasts & Podcasts Abstract Library Committee Members
*This program has expired. CME credit is no longer available.

Release Date: 01/30/19
Expiration Date: 01/30/20

Target Audience:

This enduring activity has been designed to meet the educational needs of hepatologists, gastroenterologists, and other healthcare professionals involved in the management of patients with chronic viral hepatitis.

Goal Statement:

The primary goal of this CME symposium is to better understand how to effectively identify, manage, and treat patients with viral hepatitis in order to achieve viral eradication by 2030.

Educational Objectives:

After completing this program, participants should be better able to:

  • Describe recent advances in HCV management
  • Review current barriers to HCV screening, testing, and linkage to care
  • Discuss effective approaches to overcoming barriers to HCV elimination

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Chronic Liver Disease Foundation (CLDF) and the World Hepatitis Alliance (WHA). The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information visit, email, or call 1-888-565-5321.

Accredited by

Provided by

Supported by an educational grant from AbbVie.




Welcome and Introduction

Jordan Feld, MD, MPH

Breaking News: New HCV Clinical Advances

Jordan Feld, MD, MPH

What Will it Take to Achieve Global
Hepatitis Elimination by 2030:
Lessons from Country Experiences

Nick Walsh, MD, PhD

Enhancing Access to HCV Treatment in Prisons:
Lessons from the Australian Model

Alex Thompson, MBBS (Hons), PhD, FRACP

Recruiting and Training PCPs in Rural California -
One County at a Time

Norah Terrault, MD, MPH

Role of Civil Society in Hepatitis Elimination:
WHA Campaign from the Primary Care & Patient
Advocate Perspective

Su Wang, MD, MPH, FACP

TABLE DISCUSSION: Clinical Challenges and HCV
Elimination Strategies

Panel Discussion/Q&A

Closing Remarks

Jordan Feld MD, MPH

R. Phelan Chair in Translational Liver Research
Research Director, Toronto Centre for Liver Disease
Toronto General Hospital, University Health Network
Scientist, Sandra Rotman Centre for Global Health
Toronto, Ontario, Canada

Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Currently, Dr. Feld is clinician-scientist based at the Toronto General Hospital, Toronto Centre for Liver Disease and the McLaughlin-Rotman Centre for Global Health.

Speaker Disclosure

Research Support: AbbVie, Gilead, Merck, Janssen.
Consultant: AbbVie Gilead, Contravir, Medimmune, and Merck.

Norah Terrault, MD, MPH

Professor of Medicine
Director, Viral Hepatitis Center
Department of Gastroenterology/Hepatology
University of California, San Francisco
San Francisco, California, USA

Dr. Norah Terrault is a Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation. She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

Speaker Disclosure

Research Support: AbbVie, ADMA Biologics, Allergan Pharmaceuticals, Bristol Myers Squibb, Gilead Sciences, and Merck.
Consultant: ADMA Biologics and Dova Pharmaceuticals.
Continuing Medical Education: Focus Medical Communications and Practice Point Communications
Educational Material Development: CCO Hepatitis.

Alex Thompson, MBBS (hons), PhD, FRACP

Director of Gastroenterology, St. Vincent’s Hospital Melbourne
Professorial Fellow, University of Melbourne
Department of Gastroenterology, SVHM
Victoria, Australia

Alex Thompson is Professor-Director of Gastroenterology at St. Vincent's Hospital Melbourne (University of Melbourne) Director of State-wide Hepatitis Program in Victorian prisons. His research interests include models of care for hepatitis with a focus on elimination and the identification of host and viral determinants of the natural history and treatment outcomes of hepatitis B and C viruses. Alex was involved in the discovery of IL28B polymorphism as a predictor of treatment outcome in HCV. He has published widely in journals including Nature, Gastroenterology, Hepatology, Gut and Journal of Hepatology.

Speaker Disclosure

Research Support: AbbVie, Gilead Sciences, and Merck.
Consultant: AbbVie, BMS, Eisai, Gilead Sciences, and Merck.
Speakers Bureau: AbbVie, BMS, Gilead Sciences, Merck, and Roche Diagnostics.

Nick Walsh, MD, PhD

Regional Advisor for Viral Hepatitis at the
Pan American Health Organization WHO Regional Office for the Americas
Washington, District of Columbia

Nick Walsh is a medical doctor with qualifications through the Royal Australasian College of Physicians, and a clinical background in the screening, care and treatment of hepatitis, in particular B and C, and HIV in Australia and Cambodia. He also has substantial experience in a number of other clinical domains including addiction medicine, infectious diseases, emergency and internal medicine and has worked extensively in indigenous communities in northern Australia. He has a public health background with particular experience in HIV and viral hepatitis in the Asia Pacific and Australia, and has consulted since 2006 to the World Health Organization including from 2009 to WHO Headquarter's HIV department, Global Hepatitis Programme and Mental Health and Substance Abuse. He has contributed to the development of global guidance on viral hepatitis B and C and opioid overdose. He holds a PhD in epidemiology from Monash University.

He lived and worked in public health and clinic medicine in Vietnam in 2002 and in Cambodia from 2008 – 2014. From 2014 he was the focal point for viral hepatitis, within the HIV, Hepatitis and STI unit in Communicable Diseases at the World Health Organization Regional Office for the Western Pacific in Manila, Philippines. In early 2017 he moved to The Pan American Health Organization/ WHO Regional Office for the Americas as Regional Advisor for the 35 countries across the Americas and Caribbean.

Speaker Disclosure

Dr. Walsh has no relationships to disclose

Su Wang, MD, MPH, FACP

Medical Director, Center for Asian Health
Saint Barnabas Medical Center
Florham Park, NJ, USA
WHA Executive Board Member

Su Wang, MD, MPH is the Medical Director of the Center for Asian Health, a comprehensive medical practice serving the Asian community in New Jersey. Dr. Wang practices internal medicine and leads the Center's growth, outreach and grant programs as part of Saint Barnabas Medical Center (SBMC) and the RWJBH network. She also serves as the Medical Director of the newly created Saint Barnabas Liver Center. Previously, she directed the Hepatitis B Program at Charles B. Wang Community Health Center in New York City, where she led its nationally recognized programs in primary care-based hepatitis B care and community based participatory research.

Dr. Wang is on the Executive Board for the World Hepatitis Alliance, an international partner with the World Health Organization (WHO) representing viral hepatitis patients and global efforts to eliminate viral hepatitis by 2030, a goal adopted by the WHO countries. She is currently Co-Chair of the New Jersey Hepatitis B Coalition and involved with Hepatitis B United, a national coalition representing community efforts in the U.S. She has served as primary investigator for hepatitis B screening and linkage-to-care grants sponsored by the CDC and other funders, and is the lead for the FOCUS Hepatitis B/C screening program at the SBMC Emergency Department.

She received her medical degree from the University of Miami as part of the Honors Program in Medicine and obtained her Masters of Public Health from Johns Hopkins School of Public Health. She completed a combined Internal Medicine and Pediatric residency at Georgetown University Hospital and then served as an Epidemic Intelligence Service officer for the Centers for Disease Control and Prevention (CDC) at the Food and Drug Administration.

Speaker Disclosure

Research Support: Gilead Sciences.


Be the first to know about our latest upcoming programs and events!


Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2023 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.